A Phase 1b, Open-label, Age De-escalation, Dose-escalation Study to Evaluate the Safety and Immunogenicity of Different Doses of a Candidate Malaria Vaccine; Adjuvanted R21(R21/MM) in Adults, Young Children and Infants in Kilifi, Kenya
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs R 21 (Primary) ; Matrix M
- Indications Falciparum malaria
- Focus Adverse reactions
- 09 May 2019 Status changed from not yet recruiting to recruiting.
- 10 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
- 16 Jul 2018 New trial record